PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $200 million of shares of its common stock. All of the shares in the offering are to be sold by PTC. PTC intends to grant the underwriter an option for a period of 30 days to purchase up to an additional $30 million of shares of common stock. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed.

RBC Capital Markets is acting as the sole book-running manager for the offering.

About PTC Therapeutics

PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.